COX-2 inhibitor, NS398, enhances fas-mediated apoptosis via modulation of the PTEN-Akt pathway in human gastric carcinoma cell lines

DNA and Cell Biology

Volumn 24, Issue 3, 2005, Pages 141-147

  Honjo, Soichiro ^a   Osaki, Mitsuhiko ^a,b   Ardyanto, Tonang Dwi ^a   Hiramatsu, Toshiki ^a   Maeta, Noritaka ^a   Ito, Hisao ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; CH 11; CYCLOOXYGENASE 2 INHIBITOR; FAS ANTIBODY; FAS ANTIGEN; GAMMA INTERFERON; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAD; PROTEIN KINASE B; THREONINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CARCINOMA; TUMOR GROWTH; TUMOR RESISTANCE;

ANTIBODIES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOWN-REGULATION; FAS LIGAND PROTEIN; FLOW CYTOMETRY; HUMANS; IN SITU NICK-END LABELING; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; NITROBENZENES; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; SULFONAMIDES; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 14944342238     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2005.24.141     Document Type: Article

References (38)

1. ADACHI, K., OSAKI, M., KASE, S., TAKEDA, A., and ITO, H. (2003). Anti-Fas antibody-induced apoptosis and its signal transduction in human gastric carcinoma cell lines. Int. J. Oncol. 23, 713-719.
2. CARDONE, M.H., ROY, N., STENNICKE, H.R., SALVESEN, G.S., FRANKE, T.F., STANBRIDGE, E., FRISCH, S., and REED, J.C. (1998). Regulation of cell death protease caspase-9 by phosphorylation. Science 282, 1318-1321.
3. CHENG, J., IMANISHI, H., AMURO, Y., and HADA, T. (2002). NS-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines. Int. J. Cancer 99, 755-761.
4. DATTA, S.R., DUDEK, H., TAO, X., MASTERS, S., FU, H., GOTOH, Y., and GREENBERG, M.E. (1997). Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91, 231-241.
5. DUBOIS, R.N., ABRAMSON, S.B., CROFFORD, L., GUPTA, R.A., SIMON, L.S., VAN DE PUTTE, L.B., and LIPSKY, P.E. (1998). Cyclooxygenase in biology and disease. FASEB J. 12, 1063-1073.
6. ELDER, D.J., HALTON, D.E., HAGUE, A., and PARASKEVA, C. (1997). Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: Independence from COX-2 protein expression. Clin. Cancer Res. 3, 1679-1683.
7. FOSSLIEN, E. (2000). Molecular pathology of cyclooxygenase-2 in neoplasia. Ann. Clin. Lab. Sci. 30, 3-21.
8. GROSCH, S., TEGEDER, I., NIEDERBERGER, E., BRAUTIGAM, L., and GEISSLINGER, G. (2001). COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 15, 2742-2744.
9. HAYASHI, H., TATEBE, S., OSAKI, M., GOTO, A., SUZUKI, Y., and ITO, H. (1997). Expression of Fas antigen and its mediation of apoptosis in human gastric cancer cell lines. Jpn. J. Cancer Res. 88, 49-55.
10. HENGARTNER, M.O. (2000). The biochemistry of apoptosis. Nature 407, 770-776.
11. KARGMAN, S.L., O'NEILL, G.P., VICKERS. P.J., EVANS, J.F., MANCINI, J.A., and JOTHY, S. (1995). Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res. 55, 2556-2559.
12. KARGMAN, S., CHARLESON, S., CARTWRIGHT, M., FRANK, J., RIENDEAU, D., MANCINI, J., EVANS, J., and O'NEILL, G. (1996). Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 111, 445-454.
13. KASE, S., OSAKI, M., HONJO, S., ADACHI, H., TSUJITANI, S., KAIBARA, N., and ITO, H. (2003). Expression of cyclo-oxygenase-2 is correlated with high intratumoral microvessel density and low apoptotic index in human esophageal squamous cell carcinomas. Virchows Arch. 442, 129-135.
14. KASE, S., OSAKI, M., HONJO, S., TAKEDA, A., ADACHI, K., ARAKI, K., and ITO, H. (2004). A selective Cyclooxygenase-2 inhibitor, NS398, inhibits cell growth and induces cell cycle arrest in the G2/M phase in human esophageal squamous cell carcinoma cells. J. Exp. Clin. Cancer Res. 23, 301-307.
15. KAWAMORI, T., RAO, C.V., SEIBERT, K., and REDDY, B.S. (1998). Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58, 409-412.
16. LENG, J., HAN, C., DEMETRIS, A.J., MICHALOPOULOS, G.K., and WU, T. (2003). Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: Evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 38, 756-768.
17. LI, J., YEN, C., LIAW, D., PODSYPANINA, K., BOSE, S., WANG, S.I., PUC, J., MILIARESIS, C., RODGERS, L., McCOMBIE, R., et al. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943-1947.
18. LI, M., WU, X. and XU, X.C. (2001). Induction of apoptosis by cyclooxygenase-2 inhibitor NS398 through a cytochrome C-dependent pathway in esophageal cancer cells. Int. J. Cancer 93, 218-223.
19. LIU, X.H., YAO, S., KIRSCHENBAUM, A., and LEVINE, A.C. (1998). NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res. 58, 4245-4249.
20. LUO, X., BUDIHARDJO, I., ZOU, H., SLAUGHTER, C., and WANG, X. (1998). Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94, 481-490.
21. MOLINA, M.A., SITJA-ARNAU, M., LEMOINE, M.G., FRAZIER, M.L., and SINICROPE. F.A. (1999). Inreased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 59, 4356-4362.
22. OSAKI, M., KASE. S., KODANI, I., WATANABE, M., ADACHI, H., and ITO, H. (2001). Expression of Fas and Fas ligand in human gastric adenomas and intestinal-type carcinomas: Correlation with proliferation and apoptosis. Gastric Cancer 4, 198-205.
23. OSAKI, M., KASE, S., ADACHI, K., TAKEDA. A., HASHIMOTO, K., and ITO, H. (2004a). Inhibition of the PI3K-Akt signaling pathway enhances the sensitivity of Fas-mediated apoptosis in human gastric carcinoma cell line, MKN-45. J. Cancer Res. Clin. Oncol. 130, 8-14.
24. OSAKI, M., OSHIMURA, M., and ITO, H. (2004b). PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9, 667-676.
25. PARK, W.S., OH, R.R., KIM, Y.S., PARK, J.Y., LEE, S.H., SHIN, M.S., KIM, S.Y., KIM, P.J., LEE, H.K., YOO, N.Y., et al. Somatic mutations in the death domain of the Fas (Apo- 1/CD95) gene in gastric cancer. J Pathol. 193, 162-168.
26. PUGAZHENTHI, S., NESTEROVA, A., SABLE, C., HEIDENREICH, K.A., BOXER, L.M., HEASLEY, L.E., and REUSCH, J.E. (2000). Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J. Biol. Chem. 275, 10761-10766.
27. QADRI, S.S., WANG. J.H., REDMOND, K.C., O'DONNELL, A.F., AHERNE, T., and REDMOND, H.P. (2002). The role of COX-2 inhibitors in lung cancer. Ann. Thorac. Surg. 74, 1648-1652.
28. STENNICKE, H.R., and SALVESEN, G.S. (2000). Caspases-Controlling intracellular signals by protease zymogen activation. Biochim. Biophys Acta 1477, 299-306.
29. TESTA, J.R., and BELLACOSA, A. (2001). AKT plays a central role in tumorigenesis. Proc. Natl. Acad. Sci. USA 98, 10983-10985.
30. TOYOSHIMA. T., KAMIJO, R., TAKIZAWA, K., SUMITANI, K., ITO, D., and NAGUMO, M. (2002). Inhibitor of cyclooxygenase-2 induces cell-cycle arrest in the epithelial cancer cell line via up-regulation of cyclin dependent kinase inhibitor p21. Br. J. Cancer 86, 1150-1156.
31. VIVANCO, I., and SAWYERS, C.L. (2002). The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2, 489-501.
32. WALLACH, D., VARFOLOMEEV, E.E., MALININ, N.L., GOLTSEV, Y.V., KOVALENKO, A.V., and BOLDIN, M.P. (1999). Tumor necrosis factor receptor and Fas signaling mechanisms. Annu. Rev. Immunol. 17, 331-367.
33. WANG, J.M., CHAO, J.R., CHEN, W, KUO, M.L., YEN, J.J, and YANG-YEN, H.F. (1999). The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol. Cell Biol. 19, 6195-6206.
34. WASKEWICH, C., BLUMENTHAL, R.D., LI, H., STEIN, R., GOLDENBERG, D.M., and BURTON, J. (2002). Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res. 62, 2029-2033.
35. WOLFF, H., SAUKKONEN, K., ANTTILA, S., KARJALAINEN, A., VAINIO, H., and RISTIMAKI, A. (1998). Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 58, 4997-5001.
36. WU, T., LENG, J., HAN, C., and DEMETRIS, A.J. (2004). The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol. Cancer Ther. 3, 299-307.
37. YAMASHITA, H., OSAKI, M., HONJO, S., YOSHIDA, H., TESHIMA, R., and ITO, H. (2003 ). A selective cyclooxygenase-2 inhibitor, NS-398, inhibits cell growth by cell cycle arrest in a human malignant fibrous histiocytoma cell line. Anticancer Res. 23, 4671-4676
38. ZIMMERMANN, K.C., SARBIA, M., WEBER, A.A., BORCHARD, F., GABBERT, H.E., and SCHROR, K. (1999). Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 59, 198-204.